Question of the Day – Wednesday June 21, 2017
Question: Can buprenorphine be used as an effective modality for the treatment of neonatal abstinence syndrome?
Question of the Day – Tuesday June 20, 2017
Question: Nephrolithiasis is a known complication associated with treatment of HIV using the protease inhibitor indinavir sulfate. What unique factor often makes the diagnosis of nephrolithiasis secondary to Indinavir difficult?
Question of the Day – Monday June 19, 2017
Question: What are the usual clinical manifestations of hyper-magnesemia?
Question of the Day – Friday June 16, 2017
Question: What are the unique aspects of norbormide rat poison?
Question of the Day – Wednesday June 14, 2017
Question: The reference cited below notes “Despite the unusually beneficial effects of clozapine, its use is limited due to potentially severe or even life-threatening adverse effects, including agranulocytosis, hepatitis, ileus, epileptic seizures, and cardiovascular effects.” What are the adverse cardiovascular effects associated with clozapine?
Question of the Day – Monday June 12, 2017
Question: Despite some warnings to the contrary, lithium is often used a treatment for bipolar disorder in females of child bearing age. During the first trimester of pregnancy, maternal use of lithium is associated with an increased risk in which category of fetal malformations?
Question of the Day – Friday June 9, 2017
Question: The cited reference notes “Acrylonitrile (AN) is an important industrial chemical used in the manufacture of acrylic and modacrylic fibers, resins, plastics, elastomers, adiponitrile, and nitrile rubber for various consumer goods. The primary routes of potential human industrial exposures to AN are inhalation and dermal contact.” What are the potential sources for nonindustrial AN exposures?
Question of the Day – Thursday June 8, 2017
Question: What is so called “bee venom therapy”?